뉴포리아 테라퓨틱스 (NEUP) 주가

뉴포리아 테라퓨틱스(NEUP)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.87 (+1.04%), 시가총액 $0.03B, 52주 범위 $3.72 ~ $20.00.

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indication

핵심 지표

• 현재가: $3.87 (+1.04%)
• 시가총액: $0.03B
• 52주 최저~최고: $3.72 ~ $20.00
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

뉴포리아 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.

뉴포리아 테라퓨틱스 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 0.95
• 순이익률: -0.38%
• 영업이익률: -0.12%

자주 묻는 질문